FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281686165> ?p ?o ?g. }

• W4281686165 endingPage "610" @default.
• W4281686165 startingPage "603" @default.
• W4281686165 abstract "Because of the limitations of current staging systems and evolving definitions, there are limited data on oligometastatic non-small cell lung cancer (NSCLC) epidemiology. The purpose of this study was to evaluate metastatic disease burden and the incidence of oligometastatic disease using recent clinical trial eligibility criteria.A cohort of patients with metastatic NSCLC, diagnosed from 2016 to 2019, were randomly sampled from a curated tumor registry. Definitions for oligometastatic disease were obtained from relevant clinical trials. The Stanford Cancer Institute Research Database was used to identify baseline patient factors, systemic and local therapy, extent and location of metastatic lesions, and survival outcomes.Among 120 patients presenting with metastatic NSCLC, the majority had de novo metastatic disease (75%) with a median of 4 metastatic lesions involving 3 organ systems. Of these, 37.5% would have been eligible for at least 1 oligometastatic trial, with 28.3% meeting criteria for the MD Anderson Cancer Center trial, 20.0% for NRG-LU002, 6.7% for SINDAS, and 16.7% for SABR-COMET. By adding malignant pleural effusions and early progression as exclusionary criteria, only 54.1% of patients with ≤3 synchronous metastases were eligible for consideration of local therapy. Early progression on systemic therapy was associated with worse survival (10.0 vs 42.4 months; P < .001), whereas presence of malignant pleural effusions was not. Of those tumors identified as oligometastatic, 44.4% received local therapy and 28.9% underwent ablative therapy to all sites. There was a trend toward greater overall survival (44.4 vs 24.9 months; P = .055) and progression-free survival (8.0 vs 5.4 months; P = .06) in patients meeting eligibility for at least 1 oligometastatic trial.Around 48% of patients with metastatic NSCLC had ≤3 metastases at presentation and 28% met clinical trial criteria for oligometastatic disease. Future research is needed to better define the oligometastatic state and identify patients most likely to benefit from local therapy." @default.
• W4281686165 created "2022-06-13" @default.
• W4281686165 creator A5001873561 @default.
• W4281686165 creator A5002961787 @default.
• W4281686165 creator A5009223649 @default.
• W4281686165 creator A5016420174 @default.
• W4281686165 creator A5027910630 @default.
• W4281686165 creator A5034377849 @default.
• W4281686165 creator A5035640724 @default.
• W4281686165 creator A5042159358 @default.
• W4281686165 creator A5055720530 @default.
• W4281686165 creator A5068077142 @default.
• W4281686165 creator A5073413027 @default.
• W4281686165 creator A5084612623 @default.
• W4281686165 creator A5087218029 @default.
• W4281686165 creator A5088372825 @default.
• W4281686165 date "2022-11-01" @default.
• W4281686165 modified "2023-10-14" @default.
• W4281686165 title "Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms" @default.
• W4281686165 cites W1147694683 @default.
• W4281686165 cites W1969531640 @default.
• W4281686165 cites W2042603587 @default.
• W4281686165 cites W2062180205 @default.
• W4281686165 cites W2461987940 @default.
• W4281686165 cites W2498309700 @default.
• W4281686165 cites W2761351587 @default.
• W4281686165 cites W2929866587 @default.
• W4281686165 cites W2939770857 @default.
• W4281686165 cites W2944301866 @default.
• W4281686165 cites W3019546741 @default.
• W4281686165 cites W3021910340 @default.
• W4281686165 cites W3131896404 @default.
• W4281686165 cites W3167146747 @default.
• W4281686165 cites W3180267546 @default.
• W4281686165 cites W3181187747 @default.
• W4281686165 cites W4205498652 @default.
• W4281686165 doi "https://doi.org/10.1016/j.ijrobp.2022.04.050" @default.
• W4281686165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35654305" @default.
• W4281686165 hasPublicationYear "2022" @default.
• W4281686165 type Work @default.
• W4281686165 citedByCount "4" @default.
• W4281686165 countsByYear W42816861652022 @default.
• W4281686165 countsByYear W42816861652023 @default.
• W4281686165 crossrefType "journal-article" @default.
• W4281686165 hasAuthorship W4281686165A5001873561 @default.
• W4281686165 hasAuthorship W4281686165A5002961787 @default.
• W4281686165 hasAuthorship W4281686165A5009223649 @default.
• W4281686165 hasAuthorship W4281686165A5016420174 @default.
• W4281686165 hasAuthorship W4281686165A5027910630 @default.
• W4281686165 hasAuthorship W4281686165A5034377849 @default.
• W4281686165 hasAuthorship W4281686165A5035640724 @default.
• W4281686165 hasAuthorship W4281686165A5042159358 @default.
• W4281686165 hasAuthorship W4281686165A5055720530 @default.
• W4281686165 hasAuthorship W4281686165A5068077142 @default.
• W4281686165 hasAuthorship W4281686165A5073413027 @default.
• W4281686165 hasAuthorship W4281686165A5084612623 @default.
• W4281686165 hasAuthorship W4281686165A5087218029 @default.
• W4281686165 hasAuthorship W4281686165A5088372825 @default.
• W4281686165 hasConcept C106159729 @default.
• W4281686165 hasConcept C120665830 @default.
• W4281686165 hasConcept C121332964 @default.
• W4281686165 hasConcept C121608353 @default.
• W4281686165 hasConcept C126322002 @default.
• W4281686165 hasConcept C143998085 @default.
• W4281686165 hasConcept C162324750 @default.
• W4281686165 hasConcept C185926286 @default.
• W4281686165 hasConcept C187625094 @default.
• W4281686165 hasConcept C2776256026 @default.
• W4281686165 hasConcept C2779134260 @default.
• W4281686165 hasConcept C530470458 @default.
• W4281686165 hasConcept C535046627 @default.
• W4281686165 hasConcept C61511704 @default.
• W4281686165 hasConcept C71924100 @default.
• W4281686165 hasConcept C72563966 @default.
• W4281686165 hasConcept C85393063 @default.
• W4281686165 hasConcept C91602232 @default.
• W4281686165 hasConceptScore W4281686165C106159729 @default.
• W4281686165 hasConceptScore W4281686165C120665830 @default.
• W4281686165 hasConceptScore W4281686165C121332964 @default.
• W4281686165 hasConceptScore W4281686165C121608353 @default.
• W4281686165 hasConceptScore W4281686165C126322002 @default.
• W4281686165 hasConceptScore W4281686165C143998085 @default.
• W4281686165 hasConceptScore W4281686165C162324750 @default.
• W4281686165 hasConceptScore W4281686165C185926286 @default.
• W4281686165 hasConceptScore W4281686165C187625094 @default.
• W4281686165 hasConceptScore W4281686165C2776256026 @default.
• W4281686165 hasConceptScore W4281686165C2779134260 @default.
• W4281686165 hasConceptScore W4281686165C530470458 @default.
• W4281686165 hasConceptScore W4281686165C535046627 @default.
• W4281686165 hasConceptScore W4281686165C61511704 @default.
• W4281686165 hasConceptScore W4281686165C71924100 @default.
• W4281686165 hasConceptScore W4281686165C72563966 @default.
• W4281686165 hasConceptScore W4281686165C85393063 @default.
• W4281686165 hasConceptScore W4281686165C91602232 @default.
• W4281686165 hasFunder F4320309499 @default.
• W4281686165 hasIssue "4" @default.
• W4281686165 hasLocation W42816861651 @default.
• W4281686165 hasLocation W42816861652 @default.

• next